Luxna Biotech

What Luxna Biotech does

Luxna Biotech Co., Ltd. is a Japanese biotechnology company founded in December 2017 and headquartered at the Techno-Alliance Complex in Suita, Osaka, that develops proprietary xenonucleic acid (XNA) chemistries for antisense oligonucleotide (ASO) therapeutics. The company's core technology consists of four modified nucleic acid platforms — AmNA™, scpBNA™, GuNA™, and 5'-CP™ — developed from nucleic acid chemistry research at Osaka University and licensed under comprehensive IP coverage, supplemented by antisense toxicity reduction technology and a proprietary sequence design system. These chemistries are positioned to offer higher target-mRNA binding affinity, improved nuclease resistance, and reduced hepatotoxicity and neurotoxicity compared to earlier LNA-based modifications, with potential applications in CNS, neuromuscular, hearing-loss, and rare genetic disease indications.

The company operates four revenue streams: collaborative drug discovery with pharmaceutical partners, XNA technology licensing, in-house drug discovery (with clinical development handled by pharma partners), and XNA monomer/amidite supply through chemical distribution and oligonucleotide manufacturing partners. Customers include Takeda (exclusive worldwide license for neurological disease targets), Servier (expanded neurological disease collaboration), Sumitomo Dainippon Pharma (intractable neurological diseases), Aligos Therapeutics, Renascience, Nissan Chemical, BioSpring GmbH (oligonucleotide manufacturing), Inabata & Co. (GuNA™ amidite distribution), and Summit Pharmaceuticals International. Through approximately JPY 2.36 billion raised across five funding rounds (2018–2025), Luxna maintains operations supported by government programs including J-Startup (2023), KSII Zebra certification, and the Nakanoshima Qross Cluster Program.

As of mid-2026, Luxna has not disclosed any clinical-stage assets, and the company continues to build its partnership network — most recently through an expanded strategic XNA partnership with BioSpring (June 2026) and a joint research initiative with KH Neochem (March 2026) combining XNA chemistry with glycan-based targeting — while generating revenue primarily from licensing fees, R&D collaboration payments, milestones, and amidite supply.

Name

Luxna Biotech

Legal name

Luxna Biotech Co., Ltd.

Website

https://luxnabiotech.co.jp

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Luxna Biotech is an Osaka-based biotechnology company that develops proprietary xeno nucleic acid (XNA) chemistries — AmNA™, scpBNA™, GuNA™, and 5'-CP™ — for antisense oligonucleotide therapeutics, licensing its platform and amidites to global pharmaceutical, biotech, and oligonucleotide-manufacturing partners.

Ownership category

akta.pro rank

Product category

Nucleic Acid Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) (HLAAADAC), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market) (HLAAADAJ)

Keywords

• Antisense oligonucleotide therapeutics
• Nucleic acid drug discovery
• Bridged nucleic acid modifications
• Phosphoramidite monomer supply
• XNA technology licensing

Headquarters

HQ city

Osaka

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Collaborative Drug Discovery Program with Pharmaceutical Companies: Co-development partnerships with pharmaceutical companies for ASO therapeutics targeting specific diseases and genes. Companies can start from screening or lead ASO optimization stages.
2. XNAs Technology Licensing Business: Licensing of proprietary XNA technologies (AmNA™, scpBNA™, GuNA™, 5'-CP™) to pharmaceutical and biotech companies for specific gene targets or therapeutic applications.
3. In-house Drug Discovery Business: Internal drug discovery targeting specific diseases in collaboration with academia. Clinical development and commercialization carried out by partner pharmaceutical companies.
4. XNAs Monomer Supply Business: Supply of XNAs monomer units (phosphoramidites) for incorporation into antisense oligonucleotides through collaboration with chemical companies.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Luxna Biotech develops and licenses proprietary Xeno Nucleic Acid (XNA) chemistries — AmNA™, scpBNA™, GuNA™, and 5'-CP™ — for use in antisense oligonucleotide (ASO) therapeutics. The company operates four business lines: (1) collaborative drug discovery with pharmaceutical companies on ASO candidates, (2) licensing of its XNA technologies to pharma and biotech partners, (3) in-house drug discovery with clinical development carried out by partner pharmaceutical companies, and (4) supply of XNA phosphoramidite monomers to oligonucleotide manufacturers.

Product overview

Luxna Biotech is a nucleic acid therapeutics company founded in December 2017 based on nucleic acid chemistry technologies accumulated at Osaka University. The company offers a comprehensive XNAs Technology Platform consisting of four modified nucleic acids (AmNA™, scpBNA™, GuNA™, and 5′-CP™) for antisense oligonucleotide therapeutics development. These technologies provide advantages including high binding affinity to target mRNA, enhanced safety with reduced liver and neurotoxicity, and potential to target previously inaccessible locations in the body. The company's business model encompasses four pillars: Collaborative Drug Discovery with pharmaceutical companies, XNAs Technology Licensing, In-house Drug Discovery, and XNAs Monomer Supply. This integrated approach allows Luxna to support the entire drug discovery pipeline from basic research through commercial supply of modified nucleic acid building blocks.

Differentiator

Problem solved

Functional benefit

Brands

• AmNA™: Amido-bridged nucleic acid platform offering improved nuclease resistance, enhanced base-specific hybridization, and reduced hepatotoxicity for antisense oligonucleotide therapeutics.
• scpBNA™
• GuNA™
• 5'-CP™

Products and services

• AmNA™ (Amido-Bridged Nucleic Acid) Amido-bridged nucleic acid modification that improves nuclease resistance and base-specific hybridization while reducing hepatotoxicity compared with earlier LNA technology; used as a building block in antisense oligonucleotide therapeutics.
• scpBNA™ (2'-O,4'-C-Spirocyclopropylene Bridged Nucleic Acid) Bridged nucleic acid analog with a spirocyclopropane ring that adds hydrophobicity to oligonucleotide sequences, enhancing binding affinity and nuclease resistance; used in antisense oligonucleotide therapeutics.
• GuNA™ (Guanidine-Bridged Nucleic Acid) Guanidine-bridged nucleic acid that applies a positive charge to the oligonucleotide chain, reducing immunotoxicity and improving binding affinity; particularly used in CNS-targeted antisense therapies.
• 5'-CP™ (5'-Cyclopropylene DNA) Structurally enhanced DNA analog that improves nuclease resistance without phosphorothioation, reducing off-target effects and hepato/neurotoxicity; used as a building block in antisense oligonucleotide therapeutics.
• Collaborative Drug Discovery Program with Pharmaceutical Companies Collaborative drug discovery service in which Luxna partners with pharmaceutical companies to develop antisense oligonucleotide therapeutics for target diseases and genes, starting either from screening or from lead ASO optimization.
• XNA Technology Licensing Business Licensing of Luxna's proprietary XNA technologies (AmNA™, scpBNA™, GuNA™, 5'-CP™) to pharmaceutical and biotech companies for use against specific gene targets or therapeutic applications, generating upfront fees, milestones, and royalties.
• In-house Drug Discovery Business Internal drug discovery program, conducted in collaboration with academia, that identifies and develops lead antisense oligonucleotide compounds for specific diseases; clinical development and commercialization are carried out by partner pharmaceutical companies.
• XNA Monomer (Phosphoramidite) Supply Business Supply of Luxna's XNA monomer units (phosphoramidites) for incorporation into antisense oligonucleotides, delivered through collaboration with chemical trading and distribution partners.

Quantifiable outcome

• Significantly decreased hepatotoxicity risk compared to earlier LNA technology, as demonstrated in published research and collaborative studies.
• +3 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

17 partnerships are on record, tiered supporting, core and minor.

• Inabata & Co., Ltd.supportingChannel Partner/ Reseller/ Distributor · 13 March 2026License agreement granting Inabata rights to manufacture and sell modified nucleic acid GuNA™ amidite developed using Luxna's XNAs technology. Luxna receives undisclosed upfront payment along with potential milestone payments and royalties based on future production and sales. Partnership leverages Inabata's global chemical sales network.
• KH Neochem Co., Ltd.coreStrategic or Co-development Partner · 1 March 2026Joint research initiative launched March 2026 combining Luxna's XNA-based nucleic acid technologies with KH Neochem's glycan-based targeting capabilities to optimize pharmacokinetics and delivery performance of nucleic acid therapeutics. The approximately two-year collaboration aims to expand treatment options for cancer and other challenging diseases by enabling access to previously undruggable targets.
• BioSpring GmbHcoreTechnology or Integration · 9 October 2025Non-exclusive worldwide license agreement allowing BioSpring to manufacture oligonucleotides using Luxna's XNA amidites (AmNA™, scpBNA™, 5′-CP™). The partnership enables production of advanced oligonucleotides with improved binding affinity, stability, and reduced toxicity. In December 2025, the companies announced expanded collaboration for drug discovery research to translate Luxna's XNA chemistry into clinical solutions. Further expansion announced June 2026 focusing on strategic XNA partnership.
• Summit Pharmaceuticals International CorporationsupportingChannel Partner/ Reseller/ Distributor · 17 December 2024License agreement for manufacture and sale of Luxna's artificially modified nucleic acid amidite. Partnership expands distribution reach for Luxna's modified nucleic acid building blocks.
• Renascience, Inc.supportingStrategic or Co-development Partner · 24 June 2024Collaboration agreement to develop antisense oligonucleotides for treating hereditary neurological intractable diseases.
• ServiercoreStrategic or Co-development Partner · 26 April 2024Expanded collaboration with global pharmaceutical group Servier (Headquarters: Suresnes, France) on collaborative drug discovery research in neurological diseases. Initial collaboration began April 2023, followed by option agreement in December 2023, and expansion in April 2024. Partnership leverages Luxna's xeno nucleic acid technology for neurological disease therapeutics.
• Tohoku UniversitysupportingStrategic or Co-development Partner · 22 December 2023Collaboration with Head Office for Open Innovation Business Development Strategy and Department of Otolaryngology-Head and Neck Surgery to create antisense oligonucleotide for treatment of hearing loss.
• Axcelead Drug Discovery Partners, Inc.supportingStrategic or Co-development Partner · 3 July 2023Collaborative research using XNAs technology resulting in publication on hepatotoxicity reduction profiles of antisense oligonucleotides containing AmNA and scpBNA in Nucleic Acid Therapeutics journal (March 2025).
• Sekisui Medical CO., Ltd.supportingStrategic or Co-development Partner · 3 July 2023Collaborative research on highly-sensitive detection methods for antisense oligonucleotides using Probe Alteration-Linked Self-Assembly Reaction (PALSAR) technology. Research published in BioTechniques journal.
• Takeda Pharmaceutical Company LimitedcoreTechnology or Integration · 24 February 2022Exclusive worldwide license agreement for use of Luxna's breakthrough xeno nucleic acid technology for multiple undisclosed target genes in the area of neurological diseases. This represents a significant validation of Luxna's technology platform.
• Aligos Therapeutics, Inc.supportingTechnology or Integration · 10 December 2021Worldwide re-license right agreement for innovative modified nucleic acid technology targeting multiple genes in specific diseases. Development milestone achieved in December 2021 with milestone payment received. Initial license agreement signed January 2019.
• Sumitomo Dainippon Pharma Co., Ltd.supportingStrategic or Co-development Partner · 24 April 2020Collaboration agreement combining Sumitomo Dainippon Pharma's knowledge in psychiatry and neurology drug discovery with Luxna's oligonucleotide therapeutics technology based on bridged nucleic acids. Goal is to create oligonucleotide therapeutics for multiple intractable neurological diseases targeting specific genes.
• Aichi Medical UniversitysupportingStrategic or Co-development Partner · 8 October 2019Collaboration agreement for drug discovery of spinal cord injury with neural regeneration promoting effect, supported by AMED's Drug Discovery Support Network. Aims to build industrial base for oligonucleotide therapeutics based on modified nucleic acid technology from Japan.
• Open Circle Partners LLCminorImplementation/ SI/ Consulting Partner · 2 September 2018Strategic cooperation agreement for development of oligonucleotide therapeutics and CMC consultation services.
• Nissan Chemical Co., Ltd.supportingStrategic or Co-development Partner · 6 July 2018Oligonucleotide therapeutics discovery collaboration to create new oligonucleotide therapeutics based on novel structures by combining both companies' oligonucleotide therapeutics drug discovery platform technologies.
• National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN)supportingStrategic or Co-development Partner · 2 April 2018Collaboration agreement for oligonucleotide therapeutics development based on technologies accumulated at Osaka University.
• Osaka UniversitycoreStrategic or Co-development Partner · 1 April 2018Foundational collaboration agreement for development and commercialization of technologies from Professor Satoshi Obika's laboratory. Luxna was established to commercialize Prof. Obika's nucleic acid chemistry technologies. Company maintains ongoing relationship with university through technical advisor.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Wave Life Sciences: Wave's PRISM platform develops stereopure nucleic acid therapeutics (including XNA-like modifications) for ASO and RNAi applications. It is the closest direct competitor to Luxna in modified nucleic acid chemistry for antisense oligonucleotide drug development.
• Aligos Therapeutics: Aligos is a nucleic acid therapeutics company developing antisense and oligonucleotide-based therapies. It is both a current Luxna licensee (re-license agreement signed 2019 with development milestone achieved 2021) and a direct peer pursuing comparable chemistry strategies.

Broad incumbents

• Ionis Pharmaceuticals: Ionis is the established leader in antisense oligonucleotide therapeutics with multiple approved drugs and a broad pipeline. It competes for the same pharma licensing and partnership attention as Luxna, and represents the benchmark incumbent in the ASO space.
• Alnylam Pharmaceuticals: Alnylam is the dominant company in RNAi-based therapeutics using chemically modified nucleic acids (siRNA). It competes for pharma partnership mindshare and represents the broader incumbent in RNA-targeted drug modality where Luxna operates.
• Sarepta Therapeutics: Sarepta develops nucleic acid-based therapeutics (PMO and siRNA) primarily for neuromuscular diseases. It is a broader incumbent in the oligonucleotide therapeutics space and a potential competitor for neurological disease partnership opportunities.

Emerging players

• Stoke Therapeutics: Stoke develops antisense oligonucleotides for genetic diseases using TANGO-like target augmentation approaches. It competes with Luxna in neurological and rare genetic disease indications where modified nucleic acid chemistries are required.
• ProQR Therapeutics: ProQR develops RNA-targeted oligonucleotide therapeutics (Axiomer platform) for genetic disorders. It overlaps with Luxna in therapeutic area (rare and genetic neurological diseases) and in nucleic acid-based modality.

Regional players

• Nippon Shinyaku: Nippon Shinyaku is a Japanese pharmaceutical company with a commercial oligonucleotide portfolio (e.g., NS-065/NCNP-01 for Duchenne). It is a Japan-based regional peer that overlaps with Luxna in ASO therapeutics for rare diseases.

Others

• Nitto Denko Avecia: Avecia (Nitto Denko group) is a leading oligonucleotide CDMO offering scale-up and manufacturing services. It serves as an adjacent infrastructure player in the same value chain that Luxna monetizes via its monomer supply and licensing business.
• BioSpring GmbH: BioSpring is a leading oligonucleotide CDMO that has taken a non-exclusive worldwide license to manufacture oligonucleotides using Luxna's XNA amidites and is also expanding into drug discovery collaboration. It sits at the intersection of customer and adjacent CDMO peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Luxna Biotech